eMedicine Specialties > Pediatrics: Cardiac Disease and Critical Care Medicine > Cardiology

Holt-Oram Syndrome: Treatment & Medication

Author: Poothirikovil Venugopalan, MBBS, MD, FRCP (Glasg), FRCPCH, Consulting Staff, Department of Child Health, University Hospital of Hartlepool, UK
Contributor Information and Disclosures

Updated: Nov 7, 2008

Treatment

Medical Care

  • Acute-stage management in patients with Holt-Oram syndrome (HOS)
    • Treatment is directed at the cardiac manifestations.
    • Establish a complete diagnosis.
    • Counsel the patient and family.

Surgical Care

  • Treatment for the heart defect
    • Appropriate surgical or nonsurgical correction of the heart defect if indicated and possible
    • Palliative surgery, as indicated, if complete correction is not possible
  • Treatment for musculoskeletal defects
    • Take adequate measures to prevent acquired deformities and to treat existing deformities.
    • Surgical management of hand anomalies depends on the age, pattern, and degree of accompanying malformations of the upper limb.
    • Pollicization to improve function of index finger is recommended for patients with aplasia of the thumb. This is also recommended following amputation of a rudimental thumb.

Consultations

  • Pediatric cardiologist
  • Orthopedic specialist
  • Radiologist
  • Nuclear medicine specialist
  • Family physician
  • Occupational therapist
  • Physiotherapist
  • Psychologist
  • School teacher
  • Specialist nurse
  • Pharmacist
  • Dietitian

Diet

  • Diet may require modification because of the specific cardiac abnormality.

Activity

  • No restrictions are required unless specific cardiac abnormality indicates otherwise.

Medication

The specific cardiac defect and its effects dictate appropriate therapy. For example, treatment of congestive heart failure may include diuretics, an ACE inhibitor, and digoxin. Iron supplements are appropriate in patients with cyanotic heart disease.

Bacterial endocarditis prophylaxis is administered to patients with Holt-Oram syndrome (HOS) based on the specific cardiac condition. An isolated secundum atrial septal defect (ASD) does not require this treatment. For more information, see Antibiotic Prophylactic Regimens for Endocarditis.

Diuretics

These agents eliminate retained fluid and lower preload.


Furosemide (Lasix)

Increases excretion of water by interfering with chloride-binding cotransport system, which, in turn, inhibits sodium and chloride reabsorption in ascending loop of Henle and distal renal tubule. DOC in acute heart failure and in exacerbations of CHF. Used for the long-term management of CHF.

Adult

20-80 mg/d PO/IV/IM; titrate up to 600 mg/d for severe edematous states

Pediatric

1-2 mg/kg/dose PO; not to exceed 6 mg/kg/dose; do not administer more frequently than q6h
0.5-2 mg/kg/d IV divided q8h; may titrate upward; not to exceed 6 mg/kg/d

Metformin decreases furosemide concentrations; furosemide interferes with hypoglycemic effect of antidiabetic agents and antagonizes muscle-relaxing effect of tubocurarine; auditory toxicity appears to be increased with coadministration of aminoglycosides and furosemide (varying degrees of hearing loss may occur); anticoagulant activity of warfarin may be enhanced when administered concurrently; increased plasma lithium levels and toxicity are possible when administered concurrently

Documented hypersensitivity; hepatic coma, anuria, and state of severe electrolyte depletion

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Monitor for hypokalemia, hyponatremia, and hypotension; use caution in pregnancy and breastfeeding


Spironolactone (Aldactone)

A potassium-sparing diuretic. For management of edema resulting from excessive aldosterone excretion. Competes with aldosterone for receptor sites in distal renal tubules, increasing water excretion while retaining potassium and hydrogen ions.

Adult

25-200 mg/d PO qd or divided bid

Pediatric

1.5-3.5 mg/kg/d PO divided q6-24h

May decrease effect of anticoagulants; potassium and potassium-sparing diuretics may increase toxicity of spironolactone

Documented hypersensitivity; anuria, renal failure, or hyperkalemia

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

GI upset, hyponatremia, hyperkalemia, lethargy, confusion, impotence and gynecomastia; caution in renal and hepatic impairment


Amiloride (Midamor)

Potassium-sparing diuretic that acts directly on the distal renal tubule. Usually used along with a potassium-losing diuretic.

Adult

5-10 mg PO bid

Pediatric

0.2 mg/kg PO bid

ACE inhibitors, cyclosporine, indomethacin, and potassium supplements increase risk of hyperkalemia; NSAIDs decrease the effect of amiloride; amiloride increases the risk of toxicity with lithium and amantadine

Documented hypersensitivity; hyperkalemia, potassium supplementation, or potassium-sparing diuretics; impaired renal function

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

GI upset, dry mouth, skin rash, confusion, postural hypotension, hyperkalemia, and hyponatremia

ACE inhibitors

These agents reduce afterload and decrease myocardial remodeling that worsen chronic heart failure.


Captopril (Capoten)

Widely accepted as an essential part of CHF treatment. Improves symptoms and prolongs survival. Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, resulting in lower aldosterone secretion.

Adult

6.25-12.5 mg PO tid; not to exceed 150 mg tid

Pediatric

Infants: 0.1-0.5 mg/kg/dose PO q8-12h; not to exceed 4 mg/kg/d
Children: 0.1-2 mg/kg/dose PO q8-12h; not to exceed 6 mg/kg/d
Adolescents: 6.25-25 mg/dose PO q8-12h

NSAIDs may reduce hypotensive effects of captopril; ACE inhibitors may increase digoxin, lithium, and allopurinol levels; rifampin decreases captopril levels; probenecid may increase captopril levels; the hypotensive effects of ACE inhibitors may be enhanced when given concurrently with diuretics

Documented hypersensitivity; renal impairment

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Pregnancy category D in second and third trimester; caution in renal impairment, valvular stenosis, or severe congestive heart failure

Cardiac glycosides

These agents improve symptoms, exert a positive inotropic effect on both the normal and failing heart, and are mediated through inhibition of transmembranous active transport of sodium and potassium. Clinically important actions are on the sinoatrial (SA) and AV nodes. Cardiac glycosides increase efferent vagal impulses, reflexly reduce sympathetic tone, and decrease the sinus rate. They decrease conduction velocity through the AV node.


Digoxin (Lanoxin)

Improves myocardial contractility, reduces heart rate, and lowers sympathetic stimulation in chronic heart failure.

Adult

0.125-0.375 mg PO qd

Pediatric

5-10 mcg/kg/d PO divided q12h

Medications that may increase digoxin levels include alprazolam, benzodiazepines, bepridil, captopril, cyclosporine, propafenone, propantheline, quinidine, diltiazem, aminoglycosides, PO amiodarone, anticholinergics, diphenoxylate, erythromycin, felodipine, flecainide, hydroxychloroquine, itraconazole, nifedipine, omeprazole, quinine, ibuprofen, indomethacin, esmolol, tetracycline, tolbutamide, and verapamil; medications that may decrease serum digoxin levels include aminoglutethimide, antihistamines, cholestyramine, neomycin, penicillamine, aminoglycosides, oral colestipol, hydantoins, hypoglycemic agents, antineoplastic treatment combinations (including carmustine, bleomycin, methotrexate, cytarabine, doxorubicin, cyclophosphamide, vincristine, and procarbazine), aluminum or magnesium antacids, rifampin, sucralfate, sulfasalazine, barbiturates, kaolin/pectin, and aminosalicylic acid

Documented hypersensitivity; beriberi heart disease, idiopathic hypertrophic subaortic stenosis, constrictive pericarditis, and carotid sinus syndrome

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Hypokalemia may reduce positive inotropic effect of digitalis; IV calcium may produce arrhythmias in digitalized patients; hypercalcemia predisposes patient to digitalis toxicity, and hypocalcemia can make digoxin ineffective until serum calcium levels are normal; magnesium replacement therapy must be instituted in patients with hypomagnesemia to prevent digitalis toxicity; patients diagnosed with incomplete AV block may progress to complete block when treated with digoxin; exercise caution in hypothyroidism, hypoxia, and acute myocarditis

Beta-adrenoceptor blockers

These agents relieve infundibular spasm in hypercyanotic spells.


Propranolol (Inderal)

Inhibits both beta1- and beta2-adrenergic receptors. The exact mechanism of benefit is uncertain, although it is believed to relieve infundibular spasm that precipitates hypercyanotic spells.

Adult

Not used for this indication

Pediatric

1-2 mg/kg/d PO divided bid/tid
0.01-0.1 mg/kg/dose IV administered slowly (over at least 10 min) in ICU; not to exceed 1 mg/dose in infants or 3 mg/dose in children

Coadministration with aluminum salts, barbiturates, NSAIDs, penicillins, calcium salts, cholestyramine, and rifampin may decrease propranolol effects; calcium channel blockers, cimetidine, loop diuretics, and MAOIs may increase toxicity of propranolol; toxicity of hydralazine, haloperidol, benzodiazepines, and phenothiazines may increase with propranolol

Documented hypersensitivity; uncompensated CHF; bradycardia; cardiogenic shock; AV conduction abnormalities

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Beta-adrenergic blockade may decrease signs of acute hypoglycemia and hyperthyroidism; abrupt withdrawal may exacerbate symptoms of hyperthyroidism, including thyroid storm (withdraw drug slowly and monitor closely)

More on Holt-Oram Syndrome

Overview: Holt-Oram Syndrome
Differential Diagnoses & Workup: Holt-Oram Syndrome
Treatment & Medication: Holt-Oram Syndrome
Follow-up: Holt-Oram Syndrome
Multimedia: Holt-Oram Syndrome
References
[ CLOSE WINDOW ]

References

  1. Postma AV, van de Meerakker JB, Mathijssen IB, et al. A gain-of-function TBX5 mutation is associated with atypical Holt-Oram syndrome and paroxysmal atrial fibrillation. Circ Res. Jun 6 2008;102(11):1433-42. [Medline].

  2. Ogur G, Gul D, Lenk MK, Imirzalioglu N, Alpay F, Ogur E. Variable clinical expression of Holt-Oram syndrome in three generations. Turk J Pediatr. Oct-Dec 1998;40(4):613-8. [Medline].

  3. Goldfarb CA, Wall L, Manske PR, et al. Radial longitudinal deficiency: the incidence of associated medical and musculoskeletal conditions. J Hand Surg [Am]. Sep 2006;31(7):1176-82. [Medline].

  4. Garavelli L, De Brasi D, Verri R, Guareschi E, Cariola F, Melis D, et al. Holt-Oram syndrome associated with anomalies of the feet. Am J Med Genet A. May 1 2008;146A(9):1185-9. [Medline].

  5. Mglinets VA. [Hand dermatoglyphics in patients with isolated triphalangia and Holt-Oram syndrome]. Genetika. Aug 1995;31(8):1147-53. [Medline].

  6. Tseng YR, Su YN, Lu FL, et al. Holt-Oram syndrome with right lung agenesis caused by a de novo mutation in the TBX5 gene. Am J Med Genet A. May 1 2007;143A(9):1012-4. [Medline].

  7. Smets K, Mortier G, Zecic A. Perinatal/neonatal case presentation: unexpected severe respiratory insufficiency in a newborn with Holt-Oram Syndrome. J Perinatol. Nov 2005;25(11):745-6. [Medline].

  8. Allanson JE, Newbury-Ecob RA. Holt-Oram syndrome: is there a "face"?. Am J Med Genet A. May 1 2003;118(4):314-8. [Medline].

  9. Basson CT, Cowley GS, Solomon SD, et al. The clinical and genetic spectrum of the Holt-Oram syndrome (heart-hand syndrome). N Engl J Med. Mar 31 1994;330(13):885-91. [Medline]. [Full Text].

  10. Basson CT, Huang T, Lin RC, et al. Different TBX5 interactions in heart and limb defined by Holt-Oram syndrome mutations. Proc Natl Acad Sci U S A. Mar 16 1999;96(6):2919-24. [Medline]. [Full Text].

  11. Basson CT, Solomon SD, Weissman B, et al. Genetic heterogeneity of heart-hand syndromes. Circulation. Mar 1 1995;91(5):1326-9. [Medline]. [Full Text].

  12. Benson DW, Basson CT, MacRae CA. New understandings in the genetics of congenital heart disease. Curr Opin Pediatr. Oct 1996;8(5):505-11. [Medline].

  13. Bohm M. Holt-Oram syndrome. Circulation. Dec 8 1998;98(23):2636-7. [Medline]. [Full Text].

  14. Borozdin W, Bravo Ferrer Acosta AM, Bamshad MJ, et al. Expanding the spectrum of TBX5 mutations in Holt-Oram syndrome: detection of two intragenic deletions by quantitative real time PCR, and report of eight novel point mutations. Hum Mutat. Sep 2006;27(9):975-6. [Medline].

  15. Borozdin W, Bravo-Ferrer Acosta AM, Seemanova E, et al. Contiguous hemizygous deletion of TBX5, TBX3, and RBM19 resulting in a combined phenotype of Holt-Oram and ulnar-mammary syndromes. Am J Med Genet A. Sep 1 2006;140(17):1880-6. [Medline].

  16. Bossert T, Walther T, Gummert J, et al. Cardiac malformations associated with the Holt-Oram syndrome--report on a family and review of the literature. Thorac Cardiovasc Surg. Oct 2002;50(5):312-4. [Medline].

  17. Brassington AM, Sung SS, Toydemir RM, et al. Expressivity of Holt-Oram syndrome is not predicted by TBX5 genotype. Am J Hum Genet. Jul 2003;73(1):74-85. [Medline]. [Full Text].

  18. Brockhoff CJ, Kober H, Tsilimingas N, et al. Holt-Oram syndrome. Circulation. Mar 16 1999;99(10):1395-6. [Medline]. [Full Text].

  19. Bruneau BG, Logan M, Davis N, et al. Chamber-specific cardiac expression of Tbx5 and heart defects in Holt-Oram syndrome. Dev Biol. Jul 1 1999;211(1):100-8. [Medline].

  20. Cachat F, Rapatsalahy A, Sekarski N, Hurni M, von Segesser L, Payot M. [Three different types of atrial septal defects in the same family]. Arch Mal Coeur Vaiss. May 1999;92(5):667-9. [Medline].

  21. Cheng TO. Persistent left superior vena cava in Holt-Oram syndrome. Int J Cardiol. Oct 2000;76(1):83, 81-2. [Medline].

  22. DuPre CT, Fincher RM. Holt-Oram syndrome associated with hypoplastic peripheral vasculature and midsystolic click. South Med J. Apr 1993;86(4):453-6. [Medline].

  23. Ekure EN, Okoromah CN, Briggs E, Ajenifuja OA. Holt-Oram syndrome with hypoplastic left heart syndrome in an African child. Niger Postgrad Med J. Sep 2004;11(3):190-2. [Medline].

  24. Fan C, Liu M, Wang Q. Functional analysis of TBX5 missense mutations associated with Holt-Oram syndrome. J Biol Chem. Mar 7 2003;278(10):8780-5. [Medline]. [Full Text].

  25. Gruenauer-Kloevekorn C, Reichel MB, Duncker GI, Froster UG. Molecular genetic and ocular findings in patients with holt-oram syndrome. Ophthalmic Genet. Mar 2005;26(1):1-8. [Medline].

  26. Hatcher CJ, Kim MS, Mah CS, et al. TBX5 transcription factor regulates cell proliferation during cardiogenesis. Dev Biol. Feb 15 2001;230(2):177-88. [Medline].

  27. He J, McDermott DA, Song Y, et al. Preimplantation genetic diagnosis of human congenital heart malformation and Holt-Oram syndrome. Am J Med Genet A. Apr 1 2004;126(1):93-8.

  28. Heinritz W, Moschik A, Kujat A, et al. Identification of new mutations in the TBX5 gene in patients with Holt-Oram syndrome. Heart. Mar 2005;91(3):383-4. [Medline]. [Full Text].

  29. Heinritz W, Shou L, Moschik A, Froster UG. The human TBX5 gene mutation database. Hum Mutat. Oct 2005;26(4):397. [Medline].

  30. Holt M, Oram S. Familial heart disease with skeletal malformations. Br Heart J. Apr 1960;22:236-42. [Medline].

  31. Horb ME, Thomsen GH. Tbx5 is essential for heart development. Development. Apr 1999;126(8):1739-51. [Medline]. [Full Text].

  32. Hurst JA, Hall CM, Baraitser M. The Holt-Oram syndrome. J Med Genet. Jun 1991;28(6):406-10. [Medline].

  33. Keller BB. Developmental structure-function insights from Tbx5(del/+) mouse model of Holt-Oram syndrome. Am J Physiol Heart Circ Physiol. Sep 2005;289(3):H975-6. [Medline]. [Full Text].

  34. Kohlhase J, Chitayat D, Kotzot D, et al. SALL4 mutations in Okihiro syndrome (Duane-radial ray syndrome), acro-renal-ocular syndrome, and related disorders. Hum Mutat. Sep 2005;26(3):176-83. [Medline].

  35. Koishizawa T, Hayashi N, Tadokoro M, et al. [A case report of the radical correction of a truncus arteriosus and peripheral pulmonary stenosis in association with Holt-Oram syndrome]. Kyobu Geka. Feb 1995;48(2):133-6. [Medline].

  36. Koutlas ED, Papageorgiou AA, Athyros VG. Holt-Oram syndrome with malformations of renal and cerebral arteries. Acta Cardiol. 1996;51(4):373-6. [Medline].

  37. Le Meur N, Goldenberg A, Michel-Adde C, et al. Molecular characterization of a 14q deletion in a boy with features of Holt-Oram syndrome. Am J Med Genet A. May 1 2005;134(4):439-42. [Medline].

  38. Lee ML, Tsao LY, Wang YM. Interventional cardiac catheterization for the coarctation of the aortic arch and patent ductus arteriosus in a 3-day-old neonate with the Holt-Oram syndrome. Int J Cardiol. Jun 8 2005;101(3):503-5. [Medline].

  39. Lehner R, Goharkhay N, Tringler B, et al. Pedigree analysis and descriptive investigation of three classic phenotypes associated with Holt-Oram syndrome. J Reprod Med. Mar 2003;48(3):153-9. [Medline].

  40. McDermott DA, Bressan MC, He J, et al. TBX5 genetic testing validates strict clinical criteria for Holt-Oram syndrome. Pediatr Res. Nov 2005;58(5):981-6. [Full Text].

  41. McDermott DA, He J, Song YS, et al. Update: PGD and Holt-Oram syndrome. Am J Med Genet A. Jul 15 2005;136(2):223. [Medline].

  42. Moskowitz IP, Pizard A, Patel VV, et al. The T-Box transcription factor Tbx5 is required for the patterning and maturation of the murine cardiac conduction system. Development. Aug 2004;131(16):4107-16. [Medline]. [Full Text].

  43. Murakami M, Nakagawa M, Olson EN, Nakagawa O. A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. Proc Natl Acad Sci U S A. Dec 13 2005;102(50):18034-9. [Medline]. [Full Text].

  44. Newbury-Ecob RA, Leanage R, Raeburn JA, Young ID. Holt-Oram syndrome: a clinical genetic study. J Med Genet. Apr 1996;33(4):300-7. [Medline].

  45. Pizard A, Burgon PG, Paul DL, et al. Connexin 40, a target of transcription factor Tbx5, patterns wrist, digits, and sternum. Mol Cell Biol. Jun 2005;25(12):5073-83. [Medline]. [Full Text].

  46. Plageman TF, Yutzey KE. Microarray analysis of Tbx5-induced genes expressed in the developing heart. Dev Dyn. Oct 2006;235(10):2868-80. [Medline].

  47. Porsch M, Hofmeyer K, Bausenwein BS, et al. Isolation of a Drosophila T-box gene closely related to human TBX1. Gene. Jun 8 1998;212(2):237-48. [Medline].

  48. Schneider MD, Schwartz RJ. Heart or hand? Unmasking the basis for specific Holt-Oram phenotypes. Proc Natl Acad Sci U S A. Mar 16 1999;96(6):2577-8. [Medline]. [Full Text].

  49. Shono S, Higa K, Kumano K, Dan K. Holt-Oram syndrome. Br J Anaesth. Jun 1998;80(6):856-7. [Medline]. [Full Text].

  50. Sinkovec M, Petrovic D, Volk M, Peterlin B. Familial progressive sinoatrial and atrioventricular conduction disease of adult onset with sudden death, dilated cardiomyopathy, and brachydactyly. A new type of heart-hand syndrome?. Clin Genet. Aug 2005;68(2):155-60. [Medline].

  51. Smets K, Mortier G, Zecic A. Perinatal/neonatal case presentation: unexpected severe respiratory insufficiency in a newborn with Holt-Oram Syndrome. J Perinatol. Nov 2005;25(11):745-6. [Medline].

  52. Terrett JA, Newbury-Ecob R, Smith NM, et al. A translocation at 12q2 refines the interval containing the Holt-Oram syndrome 1 gene. Am J Hum Genet. Dec 1996;59(6):1337-41. [Medline].

  53. Tucker KJ, Murphy J, Conti JB, Curtis AB. Syncope and sinus arrest associated with the upper limb-cardiovascular (Holt-Oram) syndrome. Pacing Clin Electrophysiol. Oct 1994;17(10):1678-80. [Medline].

  54. Weber M, Wenz W, van Riel A, et al. [The Holt-Oram syndrome. Review of the literature and current orthopedic treatment concepts]. Z Orthop Ihre Grenzgeb. Jul-Aug 1997;135(4):368-75. [Medline].

  55. Wilson GN. Correlated heart/limb anomalies in Mendelian syndromes provide evidence for a cardiomelic developmental field. Am J Med Genet. Apr 1 1998;76(4):297-305. [Medline].

  56. Yi CH, Terrett JA, Li QY, et al. Identification, mapping, and phylogenomic analysis of four new human members of the T-box gene family: EOMES, TBX6, TBX18, and TBX19. Genomics. Jan 1 1999;55(1):10-20. [Medline].

  57. Zaragoza MV, Lewis LE, Sun G, et al. Identification of the TBX5 transactivating domain and the nuclear localization signal. Gene. Apr 14 2004;330:9-18. [Medline].

  58. Zhou YQ, Zhu Y, Bishop J, et al. Abnormal cardiac inflow patterns during postnatal development in a mouse model of Holt-Oram syndrome. Am J Physiol Heart Circ Physiol. Sep 2005;289(3):H992-H1001. [Medline]. [Full Text].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

Holt-Oram syndrome, HOS, embryonic radial ray, triphalangeal thumbs, absent thumbs, foreshortened arms, phocomelia, TBX5, atriodigital hypoplasia, cardiac-limb syndrome, cardiomelic syndrome, heart-hand syndrome, upper limb–cardiovascular syndrome, ventricular septal defect, VSD, atrial septal defect, ASD

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Poothirikovil Venugopalan, MBBS, MD, FRCP (Glasg), FRCPCH, Consulting Staff, Department of Child Health, University Hospital of Hartlepool, UK
Poothirikovil Venugopalan, MBBS, MD, FRCP (Glasg), FRCPCH is a member of the following medical societies: British Cardiac Society and Royal College of Physicians and Surgeons of Glasgow
Disclosure: Nothing to disclose.

Medical Editor

Ira H Gessner, MD, Professor Emeritus, Pediatric Cardiology
Ira H Gessner, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American Heart Association, American Pediatric Society, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from broker recommendation; Avanir Pharma Stock Investment from broker recommendation

Managing Editor

John W Moore, MD, MPH, Professor of Clinical Pediatrics, Division of Pediatric Cardiology, Mattel Children's Hospital of University of California at Los Angeles
John W Moore, MD, MPH is a member of the following medical societies: Society for Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.

CME Editor

Gilbert Herzberg, MD, Assistant Professor, Department of Pediatrics, Section of Pediatric Cardiology, New York Medical College
Gilbert Herzberg, MD is a member of the following medical societies: American Academy of Pediatrics
Disclosure: Nothing to disclose.

Chief Editor

Steven R Neish, MD, SM, Director of Pediatric Cardiology Fellowship Program, Associate Professor, Department of Pediatrics, Baylor College of Medicine
Steven R Neish, MD, SM is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, and American Heart Association
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.